Test Price
2,800 AED✅ Home Collection Available
INPPL1 Gene Opsismodysplasia Genetic Test – NGS Diagnosis in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO‑accredited next‑generation sequencing.
- Premium Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection (daily 8 AM–11 PM).
- Clinical Guidance: Post‑test telephonic result interpretation by a consultant geneticist.
- Insurance Support: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The INPPL1 gene test detects pathogenic variants causing Opsismodysplasia, a rare autosomal recessive disorder with skeletal, dermatologic, and immune manifestations. Using next‑generation sequencing (NGS) with full gene coverage, this test delivers a definitive molecular diagnosis, guiding personalized treatment and informed family planning.
| Feature | Our INPPL1 NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 99.9% Analytical Sensitivity (ISO 9001:2015) | ~95% (coverage dependent) |
| Methodology | NGS with full INPPL1 gene sequencing | Whole Exome Sequencing (indirect) |
| Turnaround Time | 3–4 Weeks | 8–12 Weeks |
| Cost (AED) | 2800 | 4500–6000 |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh – Consultant Medical Genetics (DHA ID: 9294403) – advises: “This targeted NGS test for INPPL1 provides a definitive molecular diagnosis in suspected Opsismodysplasia. However, results must be integrated with full clinical and family history. A negative result does not exclude the condition if clinical suspicion remains high; further genetic workup may be warranted.”
Pre-Test Advisory & Informed Consent
Mandatory Genetic Counselling
All patients must undergo a pre‑test genetic counselling session to provide informed consent, review family pedigree, and discuss the scope, limitations, and implications of the result – including carrier status and potential psychological impact. Consent forms comply with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Inability to provide informed consent for minors unless legal guardian authorisation is obtained.
- Recent blood transfusion or allogeneic stem cell transplant within 4 weeks may affect DNA integrity.
Emergency Red Flags
- Acute bone fracture, severe respiratory distress, or signs of active infection – seek immediate emergency care regardless of pending genetic results.
- Sudden worsening of immunological symptoms (e.g., severe skin blistering, systemic inflammation) requires urgent evaluation.
Patient FAQ & Clinical Guidance
1. What is the INPPL1 gene Opsismodysplasia test?
A: It is a next‑generation sequencing test that analyses the entire INPPL1 gene for mutations causing Opsismodysplasia – a rare autosomal recessive disorder affecting bones, skin, and the immune system. The test provides a definitive molecular diagnosis for symptomatic individuals and can identify carriers.
2. Who should consider this test?
A: Individuals with unexplained short stature, skeletal deformities, recurrent infections, and a family history of Opsismodysplasia. It is also recommended for couples with a known family mutation seeking carrier screening, and for paediatric patients with suspected skeletal dysplasia and dermatologic features.
3. How should I prepare for this test?
A: No special preparation is required. However, a mandatory pre‑test genetic counselling session will review consent, family history, and test implications. A simple blood sample (peripheral blood) is collected by our VIP mobile phlebotomy service at your convenience.
UAE Regulatory & Data Privacy Adherence
All genetic testing and data handling conform to:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the processing of genetic and health data.
- Federal Law No. 2 of 2019 – concerning the use of information and communication technology in health fields.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – ensuring patient safety and informed consent for all clinical procedures.
Our laboratory is ISO 9001:2015 certified (Cert. INT/EGQ/2509DA/3139) and operates under the direct supervision of the Dubai Health Authority (DHA Facility License No. 1143).
Clinical & Logistical Metadata
| Test Name | INPPL1 Gene Sequencing – Opsismodysplasia |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) – VIP mobile phlebotomy & cold‑chain home collection available daily 8 AM–11 PM |
| Methodology Used | Next‑Generation Sequencing (NGS) – full INPPL1 gene sequencing |
| ICD-10-CM Code | Q78.8 – Other specified osteochondrodysplasias |
| LOINC Code | 21636-6 – DNA analysis (gene sequencing) |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians